Healthcare / Medical DevicesTaiwan
$24.40
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $154.7M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
20.5x
↑EV/EBITDA
6.8x
↓ROE
4.8%
↑Gross Margin
45.9%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.4%
FCF CAGR
+65.5%
FCF margin
6.4%
FCF / Net income
1.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.40B · net income $121.1M · FCF $154.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.40B | $2.40B | $2.39B | $2.65B | $2.66B |
| Net Income | $121.1M | $121.1M | $115.2M | $152.2M | $161.4M |
| EBITDA | $284.7M | $284.7M | $256.0M | $317.8M | $304.0M |
| EPS | — | — | 1.14 | 1.50 | 1.59 |
| Gross Margin | 45.9% | 45.9% | 45.0% | 43.0% | 40.0% |
| Operating Margin | 6.6% | 6.6% | 6.1% | 7.3% | 7.0% |
| Net Margin | 5.0% | 5.0% | 4.8% | 5.7% | 6.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.13 | 0.16 | 0.22 |
| Current Ratio | 2.78 | 2.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $154.7M | $154.7M | $152.5M | $423.5M | $34.2M |
| Returns | |||||
| ROE | 4.8% | 4.8% | 4.8% | 6.5% | 7.3% |
| Valuation | |||||
| P/E | 20.50 | 20.50 | 21.84 | 19.17 | 17.74 |
| EV/EBITDA | 6.76 | 6.76 | 8.47 | 8.30 | 9.55 |
| P/B | 0.97 | 0.97 | 1.04 | 1.25 | 1.29 |
| Growth & Yield | |||||
| Revenue Growth | 0.7% | 0.7% | -9.8% | -0.6% | — |
| EPS Growth | — | — | -24.0% | -5.7% | — |
| Dividend Yield | 3.3% | 3.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.7%
Start / end P/E
n/dx → n/dx
EPS bridge
1.14 → n/d
Residual
+5.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.